The Governance Theater at Virinchi Is a Cover for the Cash Flow Story

Virinchi Limited, a small-cap Indian software company, held its last annual general meeting in September 2023. It has not had one since.

That is the first weird thing about Virinchi. The second is that shareholders just approved up to 900 million rupees in unsecured, one-year loans to two loss-making affiliates — one a subsidiary with a negative net worth, the other a biotech company run by the same promoters. And the third is that zero promoter or institutional shareholders voted on those loans. Only small retail investors showed up to rubber-stamp the plumbing.

The headline around Virinchi right now is governance theater: a long-overdue AGM date and director re-appointments. But the governance story is the cover for the cash-flow story. The real question is not who sits on the board but where shareholder capital is going and what happens when it does not come back.

The basic point is that this is not really about annual meetings or director resumes. It is about a declining SaaS business using shareholder approval mechanics to extend large, unsecured loans to promoter-connected entities that are not making money.

Let us start with the loans themselves, because the numbers tell you what the machinery is doing.

In July 2026, Virinchi shareholders approved two sets of related-party transactions. One batch, worth up to 600 million rupees, goes to Virinchi Health Care Private Limited — a subsidiary where the parent owns roughly 51 percent. The other batch, worth up to 300 million rupees, goes to Vivo Bio Tech Limited, a biotech research company that sits inside the promoter group.

Both facilities are priced at roughly 9 percent per annum. Both are unsecured. Both mature in 12 months.

Here is the part that changes how you think about the risk. Virinchi Health Care had a negative net worth of 263.6 million rupees and posted a 332.6 million rupee loss in the prior fiscal year. Vivo Bio Tech reported a 1.94 billion rupee loss in the same period. These are not companies that can service debt from operations.

So the question is not really whether 9 percent interest is fair market rate. The question is whether the borrowers have any realistic path to repayment other than another round of capital or more loans from the same source.

The voting pattern on these transactions is the funny part.

Postal ballot results showed over 90 percent of participating shareholders voted in favor of each resolution. But promoter and institutional categories recorded zero participation. The approvals came entirely from public non-institutional shareholders — small holders who received a postal ballot and took the time to vote.

That means the people with the deepest information about the promoter group finances and the subsidiary health opted not to vote. And the people voting in the affirmative were the ones least equipped to assess whether 900 million rupees in unsecured loans to loss-making affiliates is a good use of capital.

This is not necessarily fraud. It is a disclosure-and-voting structure where the most informed capital stays quiet and the least informed capital provides the rubber stamp. But it is worth noticing that the governance mechanism is working exactly the way the promoters would prefer it to.

Now, Virinchi itself is not exactly a thriving business.

The company makes a loan management system for the US microcredit industry and offers IT services across a few verticals. Revenue is in decline — the latest reported quarter saw revenue fall roughly 5.5 percent year-over-year, with a net loss per share of 2.52 rupees. The stock has roughly halved from its recent highs.

Against that backdrop, the decision to extend large unsecured loans to affiliates is not a growth play. It is a capital allocation decision that favors the promoter group broader universe over the listed company shareholders. The listed entity is the ATM, and the affiliates are the cards.

The company is also running restructuring motions. In July 2026, the board approved a slump sale of its healthcare subsidiary back to the parent, with the purchase price settled through a set-off of existing loans rather than cash. The stated rationale is to create a focused SaaS entity and unlock long-term shareholder value.

A slump sale — the transfer of a business as a going concern to another entity — is an accounting and legal mechanism. It lets a company move assets and liabilities without a line-by-line sale. In practice, when the consideration is a wash of existing loans, it is a way to restructure who owes what to whom without changing the underlying economics. The healthcare business still exists; it just has a new legal wrapper and no cash changed hands.

The promoter group relationship to the listed company runs deeper than the loans.

Vivo Bio Tech — the biotech company receiving 300 million rupees in new loans — also received 7.4 million convertible equity warrants from Virinchi in January 2026 at 28 rupees per share. Those warrants were converted into equity in February, giving Vivo Bio Tech a 5.38 percent stake in the listed company. In other words, the same entity is now both a creditor and a shareholder of Virinchi, with loans coming in the other direction.

The original promoter, Viswanath Kompella, stepped down as chairman in late 2025 and was reclassified as Advisor to the Board. M. V. Srinivasa Rao — who also serves as Virinchi whole-time director and CFO — took over as chairman. The common directors between Virinchi, its healthcare subsidiary, and Vivo Bio Tech create a web where the same people are effectively approving loans to entities they control or influence.

The Audit Committee has set the materiality threshold for related-party transactions at roughly 280 million rupees, based on Virinchi consolidated turnover. The 900 million rupee in proposed transactions exceeded that threshold, which is why shareholder approval was required. But crossing the threshold to get the approval is the whole point — once the postal ballot clears it, the loans are above board.

Here is the simplest model for what is happening.

A listed company with declining SaaS revenue needs a story for its shareholders and a source of capital for its promoter group other ventures. The solution is to combine three mechanisms: slump-sale restructuring to rearrange the corporate family tree, related-party loans to move cash to loss-making affiliates, and postal ballot voting that relies on retail participation while promoters abstain.

None of this is illegal. The transactions are disclosed, approved by the audit committee, and cleared by shareholders at arm length. The subsidiary and the promoter group entity both have credit ratings and no reported defaults. The disclosure regime is being followed.

But following the disclosure regime is not the same as creating shareholder value. The 900 million rupees is being lent to companies that lost money last year, at an interest rate that sounds normal but does not change the repayment risk, on terms that are unsecured and short-term. If the affiliates need the money in twelve months, they will need to borrow again. And the listed company — which is already losing money itself — will need to find another 900 million rupees to roll over.

The AGM date and director re-appointments are the cover story because they are the part of the process that looks like normal governance. The actual story is in the plumbing: who gets the cash, who bears the credit risk, and which classification — related party transaction rather than promoter dividend or capital distribution — makes the whole thing legally permissible while economically ambiguous.

If you hold Virinchi shares, the question to ask at the next AGM is not whether the directors are being reappointed. It is whether the 900 million rupee loan book to loss-making affiliates is being priced as an asset on the balance sheet or written off as a feature of corporate life. The answer to that will tell you who this company is really serving.